HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.